Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells

PLoS Pathogens

Volumn 7, Issue 10, 2011, Pages

  Bosque, Alberto ^a   Famiglietti, Marylinda ^a,b   Weyrich, Andrew S ^a   Goulston, Claudia ^a   Planelles, Vicente ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPARATIVE STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LATENT VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; NONHUMAN; POTENTIAL DIFFERENCE; PROTEIN EXPRESSION; VIRUS REACTIVATION; CELL CULTURE; CHEMICAL STRUCTURE; HOMEOSTASIS; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; HIV-1; HOMEOSTASIS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-7; MODELS, MOLECULAR; RECEPTORS, ANTIGEN, T-CELL; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 80055097295     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002288     Document Type: Article

References (34)

1. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009) The challenge of finding a cure for HIV infection. Science 323: 1304-1307.
2. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94: 13193-13197.
3. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
4. Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, et al. (2010) HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329: 174-180.
5. Shen L, Siliciano RF, (2008) Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 122: 22-28.
6. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A, (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
7. Zhu J, Yamane H, Paul WE, (2010) Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 28: 445-489.
8. Boyman O, Purton JF, Surh CD, Sprent J, (2007) Cytokines and T-cell homeostasis. Curr Opin Immunol 19: 320-326.
9. Michie CA, McLean A, Alcock C, Beverley PC, (1992) Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 360: 264-265.
10. Tough DF, Sprent J, (1994) Turnover of naive- and memory-phenotype T cells. J Exp Med 179: 1127-1135.
11. Surh CD, Sprent J, (2008) Homeostasis of naive and memory T cells. Immunity 29: 848-862.
12. Seddon B, Tomlinson P, Zamoyska R, (2003) Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat Immunol 4: 680-686.
13. Persaud D, Zhou Y, Siliciano JM, Siliciano RF, (2003) Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol 77: 1659-1665.
14. Douek DC, Picker LJ, Koup RA, (2003) T cell dynamics in HIV-1 infection. Annu Rev Immunol 21: 265-304.
15. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15: 893-900.
16. Bosque A, Planelles V, (2009) Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113: 58-65.
17. Messi M, Giacchetto I, Nagata K, Lanzavecchia A, Natoli G, et al. (2003) Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol 4: 78-86.
18. Bosque A, Planelles V, (2011) "Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells". Methods 53: 54-61.
19. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, et al. (2005) IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 115: 128-137.
20. Lehrman G, Ylisastigui L, Bosch RJ, Margolis DM, (2004) Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells. J Acquir Immune Defic Syndr 36: 1103-1104.
21. Scripture-Adams DD, Brooks DG, Korin YD, Zack JA, (2002) Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 76: 13077-13082.
22. Andersen JL, DeHart JL, Zimmerman ES, Ardon O, Kim B, et al. (2006) HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS Pathog 2: e127.
23. Scholzen T, Gerdes J, (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322.
24. Gondois-Rey F, Biancotto A, Pion M, Chenine AL, Gluschankof P, et al. (2001) Production of HIV-1 by resting memory T lymphocytes. AIDS 15: 1931-1940.
25. Jordan A, Bisgrove D, Verdin E, (2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. Embo J 22: 1868-1877.
26. Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner FA, et al. (2009) Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol 83: 3078-3093.
27. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, et al. (2009) IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 113: 6304-6314.
28. Yang HC, Xing S, Shan L, O'Connell K, Dinoso J, et al. (2009) Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 119: 3473-86.
29. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25: 207-212.
30. Lahm HW, Stein S, (1985) Characterization of recombinant human interleukin-2 with micromethods. J Chromatogr 326: 357-361.
31. Simm M, Shahabuddin M, Chao W, Allan JS, Volsky DJ, (1995) Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol 69: 4582-4586.
32. Schmid I, Cole SW, Korin YD, Zack JA, Giorgi JV, (2000) Detection of cell cycle subcompartments by flow cytometric estimation of DNA-RNA content in combination with dual-color immunofluorescence. Cytometry 39: 108-116.
33. Vandegraaff N, Kumar R, Hocking H, Burke TR Jr, Mills J, et al. (2001) Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother 45: 2510-2516.
34. Butler SL, Hansen MS, Bushman FD, (2001) A quantitative assay for HIV DNA integration in vivo. Nat Med 7: 631-634.